Editas Medicine, Inc. Logo

Editas Medicine, Inc.

A clinical-stage genome editing company developing CRISPR medicines for serious diseases.

EDIT | US

Overview

Corporate Details

ISIN(s):
US28106W1036
LEI:
Country:
United States of America
Address:
11 HURLEY ST., 2141 CAMBRIDGE

Description

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative medicines for serious diseases using CRISPR technology. The company's mission is to discover, develop, and commercialize durable, precision genomic therapies that can correct the underlying genetic causes of various conditions. Its proprietary platform enables the precise revision, removal, or replacement of DNA. Editas Medicine's research and development pipeline is concentrated on creating both in vivo (in-body) and ex vivo (out-of-body) gene-edited medicines to treat a broad class of diseases, with a focus on rare genetic disorders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Editas Medicine, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Editas Medicine, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Editas Medicine, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

DG INNOVATE PLC Logo
Develops sustainable technologies for electric mobility and energy storage solutions.
United Kingdom
DGI
Dianthus Therapeutics, Inc. /DE/ Logo
Clinical-stage biotech developing therapies for severe autoimmune diseases.
United States of America
DNTH
Dogwood Therapeutics, Inc. Logo
A biotech company developing novel therapeutics for pain and neuropathy.
United States of America
DWTX
DreamCIS INC. Logo
Contract research organization for pharma, biotech, and medical device industries.
South Korea
223250
DT&CRO CO., Ltd. Logo
A full-service CRO providing non-clinical and clinical studies for various industries.
South Korea
383930
D.Western Therapeutics Institute, Inc. Logo
Biotechnology firm developing drugs from a proprietary protein kinase inhibitor library.
Japan
4576
Ectin Research AB Logo
Pharmaceutical company developing novel oncology treatments, with a lead drug in trials.
Sweden
ECTIN B
EdgeLab S.p.A. Logo
Designs and manufactures marine and underwater solutions, including AUVs and robotics.
Italy
ELB
Eledon Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing therapies for organ and autoimmune diseases.
United States of America
ELDN
Elicera Therapeutics AB Logo
Clinical-stage immuno-oncology company developing cell and gene therapies for cancer.
Sweden
ELIC

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.